Interferon beta

Multiple Sclerosis

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">REBIF (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of REBIF is identical to that of natural fibroblast derived human interferon beta. Natural interferon beta and interferon beta-1a (REBIF) are glycosylated with each containing a single N-linked complex carbohydrate moiety.</p><p>Using a reference standard calibrated against the World Health Organization natural interferon beta standard (Second International Standard for Interferon, Human Fibroblast GB 23 902 531), REBIF has a specific activity of approximately 270 million international units (MIU) of antiviral activity per mg of interferon beta-1a determined specifically by an <span class="Italics">in vitro </span>cytopathic effect bioassay using WISH cells and Vesicular Stomatitis virus. REBIF 8.8 mcg, 22 mcg and 44 mcg contains approximately 2.4 million international units, 6 million international units or 12 million international units, respectively, of antiviral activity using this method.</p><p>REBIF (interferon beta-1a) is formulated as a sterile solution in a prefilled syringe or REBIF Rebidose autoinjector intended for subcutaneous (sc) injection. Each 0.5 mL (0.5 cc) of REBIF contains either 22 mcg or 44 mcg of interferon beta-1a, 2 mg or 4 mg albumin (human), 27.3 mg mannitol, 0.4 mg sodium acetate, and water for injection. Each 0.2 mL (0.2 cc) of REBIF contains 8.8 mcg of interferon beta-1a, 0.8 mg albumin (human), 10.9 mg mannitol, 0.16 mg sodium acetate, and water for injection.</p></section>

Rebif

0.5 ML interferon beta-1a 0.044 MG/ML Auto-Injector

0.5 ML interferon beta-1a 0.044 MG/ML Auto-Injector [Rebif]

0.5 ML interferon beta-1a 0.088 MG/ML Auto-Injector

0.5 ML interferon beta-1a 0.088 MG/ML Auto-Injector [Rebif]

0.2 ML interferon beta-1a 0.044 MG/ML Auto-Injector

0.2 ML interferon beta-1a 0.044 MG/ML Auto-Injector [Rebif]

0.5 ML interferon beta-1a 0.088 MG/ML Prefilled Syringe

0.5 ML interferon beta-1a 0.088 MG/ML Prefilled Syringe [Rebif]

0.2 ML interferon beta-1a 0.044 MG/ML Prefilled Syringe

0.5 ML interferon beta-1a 0.044 MG/ML Prefilled Syringe

0.5 ML interferon beta-1a 0.044 MG/ML Prefilled Syringe [Rebif]

interferon beta-1a

0.2 ML interferon beta-1a 0.044 MG/ML Prefilled Syringe [Rebif]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Reimbursement Information 

Coverage Authorization Request 

Coverage Authorization Appeals 

Enroll in Patient Savings Program 

Rebif Service Request Form 

Other HCP Resources 

About Rebif 

Side Effects

FAQs: Multiple Sclerosis

Taking Rebif

Nurse Support

Instructions for Use: Multiple Sclerosis 

Patient Brochure 

Family Planning Brochure 

Treatment Tracker 